Navigation Links
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer's Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Date:8/26/2013

OSAKA, Japan and DURHAM, N.C., Aug. 26, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), today announced the initiation of TOMMORROW, a global Phase 3 clinical trial investigating a genetic-based biomarker risk assignment algorithm (risk assignment algorithm) to predict risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period and to evaluate the efficacy of the investigational low dose pioglitazone (designated AD-4833 for this use) in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm.

The risk assignment algorithm is comprised of apolipoprotein E (APOE) and TOMM40 genotypes and age. Age and APOE genotype have previously been shown to indicate elevated risk of AD. The addition of TOMM40 is hypothesized to further refine the risk determination.

"To date, there have been a number of avenues investigated with the goal of altering the course of Alzheimer's disease but results have been unsuccessful," said Allen Roses, M.D., Chief Executive Officer, Zinfandel. "This is why the TOMMORROW trial is important. The potential to identify an individual's risk for developing MCI due to AD warrants further investigation."

AD is a devastating disease and diagnoses are increasing as the world's population ages. Currently 35.6 million people worldwide are living with some form of dementia. Studies show that individuals with MCI are at an increased risk of developing AD or another dementia with conversion rates of approximately 15 percent per year.

"AD-4833 is a member of a class of drugs known as PPAR (peroxisome proliferator-activated receptor)-gamma agonists which available data show may have a beneficial role in delaying symptoms of MCI due to AD," noted '/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Launches New Subsidiary in Peru
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
5. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
6. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
7. Takeda to Acquire Inviragen, Inc.
8. Takeda Responds to Verdict in Diabetes Drug Case
9. Takeda Launches New Subsidiary in Ecuador
10. Takeda lanza nueva subsidiaria en Ecuador
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... EHE International, the recognized leader in preventive medicine and annual ... David Abrams M.D . in Tarzana, CA ... Through David Abrams M.D ., EHE members in the ... to EHE,s preventive care programs to help proactively maintain their ... Abrams M.D. to its growing private provider network. With Dr. ...
(Date:9/16/2014)... 16, 2014  Decision Resources Group finds that the rheumatoid arthritis ... 2013 to over $18.2 billion in 2023 in the ... Germany , Italy , Spain ... Japan . TNF-alpha inhibitors will remain the leading drug ... but growth will be constrained and patient shares will decline due ...
(Date:9/16/2014)... DUBLIN , Sept. 16, 2014 ... addition of the "Global Laparoscopy Devices Industry ... The Global Laparoscopy Devices Industry Report ... the current state of the global laparoscopic devices. ... of the industry including definitions, classifications, applications and ...
Breaking Medicine Technology:EHE International Certifies David Abrams M.D. as Its Newest Partner 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Global Laparoscopy Devices Industry Report 2014 2
(Date:9/16/2014)... the University of California, San Diego School of Medicine ... assess the safety and efficacy of a new monoclonal ... most common form of blood cancer in adults. ... used by embryonic cells during early development and exploited ... the latter responsible for 90 percent of all cancer-related ...
(Date:9/16/2014)... LINCOLN, R.I. (PRWEB) September 16, 2014 ... from Sunday, Sept. 14, through Saturday, Sept. 20, ... make sure children are safe and secure while in ... from the National Traffic Highway Safety Administration (NHTSA), ... did not read the instruction manual when installing child ...
(Date:9/16/2014)... 16, 2014 CarePoint Health is ... Leigh Montes, MD, has joined our expanded Bariatric ... Hospital. Our system welcomes Dr. Montes to the ... surgical weight loss center, helps patients achieve long-term ... surgery procedures, including Gastric Sleeve, Gastric Bypass, LAP-BAND ...
(Date:9/16/2014)... Pittsburgh, PA (PRWEB) September 16, 2014 ... recovering well today after undergoing successful heart transplantation surgery ... , Mr. Tekulve, who spent most of his 16-year ... the team as a commentator for Root Sports Pittsburgh, ... his transplant surgeon, Stephen Bailey, MD, surgical director of ...
(Date:9/16/2014)... (HealthDay News) -- Illegal drug use among teens in the ... federal report. Encouragingly, the new study also found ... products among young people between the ages of 12 and ... survey of 70,000 people aged 12 and older across the ... or abuse problems among this age group also dropped from ...
Breaking Medicine News(10 mins):Health News:Novel drug targeting leukemia cells enters clinical trial 2Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:Top Bariatric Surgeon Joins CarePoint Health 2Health News:Top Bariatric Surgeon Joins CarePoint Health 3Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2
... Chemo-radiation therapy looks to kill cells on organ,s surface, ... (HealthDay News) -- Patients are being recruited for a ... protocol for pleural mesothelioma, a cancer of the lung,s ... , Currently, the standard treatment is to remove the ...
... how the nervous system and the immune system interact, scientists at The ... which the brain and the spleen communicate. , ... Manhasset, NY (PRWEB) ... nervous system and the immune system interact, scientists at The Feinstein ...
... T. Kennedy DSc, Dean of Tufts University,s Gerald J. ... Policy announced the 3rd Annual Friedman School Symposium, a ... facing industry, policy-makers, academics and thought leaders in the ... September 24th to 26th, 2008. , Fifteen experts will ...
... for Advanced Medical,Education (IAME) announces the release of ... program. Produced in response to a,strong demand by ... 3 CME,credits required for Mammography Center accreditation., ... course,available online at the CME Center of IAME,s ...
... 15 Percent Increase in Prescription Drug,Costs in ... HealthLeaders-InterStudy, NASHVILLE, Tenn., July 21 ... intelligence, reports that Excellus,BlueCross BlueShield will continue ... and public education efforts. According to the,new ...
... (SPI) has,received an R&D contract award from the ... drug candidate for hearing regeneration. SPI has,developed a ... inner ear of mammals involving p27Kip1, a cyclin ... division or proliferation in,many developing cells and tissues ...
Cached Medicine News:Health News:Lung Cancer Trial Targets Asbestos-Related Disease 2Health News:Embargoed Until Monday, July 21 at 5 p.m. EST; Scientists Figure Out How the Immune System and Brain Communicate to Control Disease 2Health News:Embargoed Until Monday, July 21 at 5 p.m. EST; Scientists Figure Out How the Immune System and Brain Communicate to Control Disease 3Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 2Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 3Health News:New York's Excellus BlueCross BlueShield to Continue Generic Medication Promotion to Help Control Costs 2Health News:Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product 2
the LabOne Healthcare Group markets laboratory testing to physicians, patients, managed care companies, self-insured employers, wellness companies and hospitals....
... ideal hemostatic gauze for a variety of inpatient ... iX is easy to handle and can be ... sites that are often a challenge faced by ... used to control bleeding in outpatient procedures such ...
Sharp tipped straight scissors. For cutting in the iris plane or cutting peripheral membranes. May also be useful in ROP cases....
Microscissors : Horizontal Scissors...
Medicine Products: